Skip to product information
1 of 1

Ambossle

The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

Regular price $20.00 USD
Regular price Sale price $20.00 USD
Sale Sold out

we'll contact you for payment after receiving your order

The University of Texas MD Anderson Cancer Center IOTOX Symposium Treating Immune-Related Adverse Events Integrating Insights from Clinical, Translational and Basic Science 2024

 Include: 3 videos + 1 pdf, size: 8.4 GB

Target Audience: allergy and immunology, internal medicine, and medical oncology, as well as pharmacists, physician associates, and trainees

Information:

Date & Location: Wednesday, November 6, 2024, 12:00 PM – Thursday, November 7, 2024, 4:00 PM, TMC3 Collaborative Building, Houston, TX
Target Audience
Specialties – Allergy and Immunology, Internal Medicine, Medical Oncology
Professions – Nurse – APRN, Nurse – LVN, Nurse – RN, Other, Pharmacist, Physician (MD or DO), Physician Associate, Student or Trainee

Overview

The IOTOX Symposium is designed to bring a diverse range of stakeholders together to foster collaboration, share cutting-edge research findings, and discuss treatment advancements in the field of immunotherapy toxicities. The Symposium will provide a platform for attendees to engage in in-depth discussions and attend presentations that highlight new methodologies, emerging technologies, and innovative clinical management strategies. By facilitating network and knowledge exchange, the Symposium seeks to drive scientific progress and translate research into practical treatment options to improve patient outcomes.

Call for Abstracts
We invite faculty, trainees and staff to submit abstracts in the areas of clinical, translational, and basic science research. Submission deadline has been extended. To be considered for oral presentation, submit by Sunday, Sept. 29, 11:59pm.

Objectives
At the conclusion of this activity, learners will be able to:
  1. Construct the guideline recommendations for each toxicity.
  2. Identify location and use of national societies guidelines for IOTOX.
  3. Implement IOTOX guidelines that are vetted by both oncologists and internal medicine specialists.
  4. Identify patient treatment plans to evaluate difficult patient circumstances as it pertains to IOTOX.
  5. Employ treatment plans and IOTOX guidelines to all providers including Pharmacists, APPs, Nurses and Trainees.

 

+ Topics:

Agenda.pdf
November 6 Part 1.mp4
November 6 Part 2.mp4
November 7.mp4

 

  • Detail:
Wednesday, November 6, 2024
Registration and Check-In
12:00PM – 1:00PM


Session 1: Welcome and Keynote Address
Welcome Remarks
1:00PM – 1:05PM
David J. Tweardy, MDOverview & Introduction of Keynote Speaker
(NO CE Credit Awarded) 

Keynote Address: Reverse Translational Approaches to Drive Clinical Breakthroughs in Cancer Immunotherapy
1:05PM – 1:50PM
Padmanee Sharma, MD, PhD

Q&A Session
1:50PM – 2:00PM


Session 2: Bedside to Bench: Integrating Clinical Practice and Translational Research in Immune-Mediated Colitis

Moderators: Adi Diab, MD; and Roza Nurieva, PhD

Clinical Management and Current Limitations in Treatment
2:00PM – 2:30PM
Yinghong Wang, MD, PhD

Clinical Trials and Translational Approaches to Solve Clinical Problems
2:30PM – 3:00PM
Michael Dougan, MD, PhD

Interrogating the role of the IL-6/IL-23-Th17 axis in Immune-Mediated Colitis
3:00PM – 3:30PM
Adi Diab, MD

Pre-Clinical Models for Investigation of Immune-Mediated Colitis
3:30PM – 4:00PM
Roza Nurieva, PhD

Q&A Session
4:00PM – 5:00PM

Break and Networking
5:00PM – 5:15PM


Session 3: Poster Presentations and Welcome Reception
Session 3: Poster Presentations and Welcome Reception
5:15PM – 6:30PM(No CE Credit Awarded) 

Thursday, November 7, 2024

Session 4: Day 2 Welcome and Keynote Address
Welcome Remarks
8:00AM – 8:05AM
Christopher R. Flowers, MD, FASCOOverview & Introduction of Keynote Speaker
(NO CE Credit Awarded) 

Keynote Address: Bridging Boundaries: National Efforts to Address Immunotherapy Toxicity
8:05AM – 8:50AM
Pauline Funchain, MD

Q&A Session
8:50AM – 9:00AM


Session 5: Round Table Discussions – Relevance of Mouse Models for Clinical Management of irAEs

Moderators: Adi Diab, MD; and Roza Nurieva, PhD

Panelists for Mouse Studies
9:05AM – 9:10AM
Seyed Javad M. Moghaddam, MD
Kristen Pauken, PhDPanelists for Mouse Studies:
Kristen Pauken, PhD; and Seyed Moghaddam, MD 

Panelists for Human Studies:
Sumit Subudhi, MD; and Ala Abudayyeh, MD

Topics to be Discussed:
• What is Heavily Conserved and Readily Modeled
• How to Translate These Findings Clinically

Q&A Session


Panelists for Human Studies
9:10AM – 9:20AM
Sumit K Subudhi, MD, PhD
Ala Abudayyeh, MD

Break
10:30AM – 10:40AM


Session 6: Clinical Challenges and Research Directions in irAEs I

Moderators: Bilal A. Siddiqui, MD; and Sebastian T. Wurster MD

Dermatologic irAEs
10:40AM – 11:00AM
Noah I Hornick, MD, PhD, FAAD
Sebastian T Wurster, MD (Moderator)

Q&A Session
11:00AM – 11:10AM

Endocrine irAEs
11:10AM – 11:30AM
Nupur Kikani, MD

Q&A Session
11:30AM – 11:40AM

Rheumatologic irAEs
11:40AM – 12:00PM
Alexa Meara, MD

Q&A Session
12:00PM – 12:10PM

Lunch
12:10PM – 1:10PM


Session 7: Clinical Challenges and Research Directions in irAEs II

Moderators: Yinghong (Mimi) Wang, MD, PhD; and Ashley Aaroe, MD

Neurologic irAEs
1:10PM – 1:30PM
Bianca Santomasso, MD, PhD

Q&A Session
1:30PM – 1:40PM

Cardiac irAEs
1:40PM – 2:00PM
Nicolas Palaskas, MD

Q&A Session
2:00PM – 2:10PM

Pulmonary irAEs
2:10PM – 2:30PM
Ajay Sheshadri, MD

Q&A Session
2:30PM – 2:40PM


Session 8: Oral Abstract Presentations

Moderators: Arielle Raugh, PhD; and Synat Keam, PhD

Reported Immunotherapy Toxicities on FDA Registration Trials for Solid Tumors – Is There More Than Meets the Eye?
2:40PM – 2:50PM
Matthew J Hadfield, DO

Q&A Session
2:50PM – 2:55PM

Mechanistic Insights on Immune Checkpoint Inhibitor-Induced Recurrent Inflammatory Arthritis
2:55PM – 3:05PM
Synat Keam Sr., PhD

Q&A Session
3:05PM – 3:10PM

Integrating Genetic and Radiographic Markers to Predict Immune Checkpoint Inhibitor Pneumonitis Risk in Non-Small Cell Lung Cancer
3:10PM – 3:20PM
Felipe Soto Lanza, MBBS,MD

Q&A Session
3:20PM – 3:25PM

Modeling Immune Checkpoint Inhibitor-Induced Colitis: Mechanistic Insights and Therapeutic Targets
3:25PM – 3:35PM
Naimah Turner, MS

Q&A Session
3:35PM – 3:40PM

Closing Remarks
3:40PM – 3:45PM
View full details